The LCAOS project will develop and test a new diagnostic tool, able to detect:
- the presence of lung cancer, and
- an increased risk of a patient developing lung cancer in the future.
Diagnostic tests currently available are unsuitable for widespread screening because they are costly, occasionally miss tumours, are not time-efficient, nor free of complications. LCAOS will overcome these problems by using an approach based on volatile biomarkers emitted from cell membranes. A multidisciplinary effort, incorporating nanotechnology, biomedical engineering, medical oncology, and computation strategies, will develop a highly-sensitive, inexpensive, and fast-response, non-invasive, artificial nose (known as, NaNose), building on the coordinator’s earlier success in this area. The NaNose will be able to detect pre-neoplastic volatile biomarkers that indicate an increased genetic risk of lung cancer, and the presence of lung cancer. It has already been established that these biomarkers can be detected either directly from the headspace of the cancer cells or via exhaled breath.
- develop arrays of chemically-sensitive field effect transistors (FETs) of non-oxidized, molecule-terminated silicon nanowires (Si NWs);
- test the ability of these devices to sense volatile lung cancer biomarkers from in-vitro tissue, and exhaled human breath;
- study the signal transduction mechanism of the volatile biomarkers, using pattern recognition;
- improve systems to enable the NaNose to distinguish the targeted biomarkers from environmental clutter, using methylation, expression profiling, and genome-wide sequencing; and
- perform clinical-related studies to assess lung cancer conditions in actual patients & tissues, and in the presence of real-world confounding signals.
You are welcome to our new issue of the LCaos Newsletter. As you know, the purpose of this newsletter is to bring you the latest news coming from our FP7 LCaos consortium activities and achievements.
June 13-14, 2013 - Saarbrücken/Wallerfangen, Germany
The LCAOS workshop is jointly organized with the Breath Analysis Summit 2013 (June 9-12, 2013) and the ISOCS Short Course on Chemical Sensors for Breath Analysis (June 14, 2013). All events take place at the same location. The LCAOS workshop aims to bring the latest updates on volatile markers for early diagnosis and classification of lung cancer. Additionally, the workshop aims to being the latest updates on chemical sensors and nanoarrays for the diagnosis of lung cancer via volatile markers. The LCAOS workshop will bring together scientists, engineers, clinicians, industry executives, and entrepreneurs to discuss key trends, future directions, and technologies available for chemical sensors and nanoarrays for lung cancer diagnosis via volatile markers.
Please register via the ISOCS website at: www.olfactionsociety.org/registration/breath2013
Final program: LCAOS Workshop 2013 program final.pdf